Madrigal (MDGL) Reports Q3 Loss, Tops Revenue Estimates
Madrigal (MDGL) came out with a quarterly loss of $5.08 per share versus the Zacks Consensus Estimate of a loss of $1.98. This compares to a loss of $4.92 per share a year ago.
Madrigal (MDGL) Expected to Beat Earnings Estimates: Should You Buy?
Madrigal (MDGL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Madrigal Pharmaceuticals: Rezdiffra Commercialization Bodes Well For Continued Growth
Madrigal Pharmaceuticals is reiterated as a Strong Buy, driven by Rezdiffra's rapid US launch and recent European approval. Q2 2025 saw Rezdiffra sales reach $213M and >23,000 patients, with Q3 expectations of $245M and continued explosive growth. MDGL's strategic GLP-1 partnership and extended patent exclusivity through 2045 position it for long-term growth in the MASH market.
Madrigal Pharma CEO talks competition in the liver disease treatment space
Bill Sibold, Madrigal Pharma CEO, joins 'Fast Money' to talk how Rezdiffra stacks up to competitors in the MASH treatment space, sales growth for the drug over the last year, and more.
Madrigal Pharmaceuticals: Rezdiffra's US And EU Rollout Remains Promising
MDGL's Rezdiffra is its main value driver. This is the first FDA-approved MASH F2–F3 therapy. So far, Rezdiffra shows a rapid U.S. uptake and market penetration. Management projects over 23,000 patients by Q2 2025. The EU also granted Rezdiffra a conditional authorization. It will soon launch in Germany, and it has a sizeable initial European target of diagnosed F2–F3 patients.
Madrigal Pharmaceuticals, Inc. (MDGL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 7:45 AM EDT Company Participants William Sibold - CEO, President & Director David Soergel - Executive VP & Chief Medical Officer Mardi Dier - Executive VP & CFO Presentation Unknown Analyst Good morning, everyone. Very excited to be kicking off the Morgan Stanley Healthcare Conference with the Madrigal team this morning.
Madrigal Gets Conditional Nod for MASH Drug Rezdiffra in EU
MDGL wins EU nod for Rezdiffra as the first and only approved MASH therapy. The drug's launch in Europe is expected in the fourth quarter of 2025.
Madrigal Pharmaceuticals: A High-Paced Launch That Could Grow Further
Rezdiffra's Q2 '25 net sales surged 55% to $212.8M, beating expectations and highlighting strong commercial momentum for Madrigal Pharmaceuticals, Inc. Despite robust revenue growth, Madrigal Pharmaceuticals still reported a net loss of $42.3M, though profitability may be near. Approval of Rezdiffra in the EU could come in August 2025, with a launch by MDGL in Germany in H2 '25 possible.
Madrigal Pharmaceuticals, Inc. (MDGL) Q2 2025 Earnings Call Transcript
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL ) Q2 2025 Earnings Conference Call August 5, 2025 8:00 AM ET Company Participants David Soergel - Executive VP & Chief Medical Officer Mardi C. Dier - Executive VP & CFO Tina E.
Madrigal (MDGL) Reports Q2 Loss, Tops Revenue Estimates
Madrigal (MDGL) came out with a quarterly loss of $1.9 per share versus the Zacks Consensus Estimate of a loss of $3.48. This compares to a loss of $7.1 per share a year ago.
Madrigal Pharmaceuticals: Rezdiffra Expansion Avenues Shift Focus To Long Term
Madrigal Pharmaceuticals, Inc.'s Rezdiffra showed strong Q1 2025 sales of $137.3M that highlight robust U.S. demand and early commercial momentum in non-cirrhotic NASH patients. Key catalysts include potential European approval in August 2025, label expansion to compensated MASH cirrhosis 2027, and new GLP-1 combo therapy trial initiation in 2026. The global license for SYH2086 aims to boost Rezdiffra's efficacy in MASH, with phase 1 combo trials expected to start in 1st half of 2026.
MDGL Stock Soars 11% on New Patent Protecting Rezdiffra Dosing Rights
Madrigal Pharmaceuticals stock jumps 11% after securing a new U.S. patent for Rezdiffra's dosing, reinforcing exclusivity through 2044.
